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Background and objectives: Type 2 diabetes (T2D) is very prevalent among the elderly. Insulin therapy is often
required for glycemic control. The association of starting this therapy with depressive symptoms as well the
health-related quality of life (HRQoL) is unknown among the elderly patients.
Aims: Evaluate the association of starting insulin therapy depressive symptoms as well with HRQoL of elderly
people with T2D.
Methods: 36 T2D participants (67.9 % females, age 66.5 years ± 5.1) were recruited, 26 of whom completed the
follow-up. Generic (Short-Form 36 Health Survey - SF-36) and specific (Problem Areas in Diabetes - PAID) HRQoL
questionnaires, Beck Depression Inventory (BDI), clinical, laboratorial and socio-demographic data were recorded
on baseline and 6 months after the beginning of insulin treatment.
Results: There was a reduction in the BDI score after the use of insulin, which means an improvement in depressive
symptoms (Before/After: median – 10.5 / 7; p = 0008). There were no statistically significant differences in HRQoL
scores between the two time periods There was also a reduction in HbA1c (Before/After: median – 8.7/7.9).
Otherwise, there were no statistically significant differences in: BMI (28.1/28.3); Abdominal circumference:(100.5/99.5)
and chronic complications status.
Conclusion: Insulin therapy in elderly people with type 2 diabetes can lead to an improvement of depressive
symptoms and does not seem to affect negatively HRQoL of the participants.
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Type 2 diabetes mellitus (T2D) is prevalent among adults,
especially among elderly people. New data from Inter-
national Federation of Diabetes (IDF) indicates that
there are currently more than 285 million people with
T2D around world. It is estimated that by 2030 this
figure will have increased to more than 552 million
people with T2D. Population growth and improvements
in public health leading to an increase on life* Correspondence: rico_de_oliveira@yahoo.com.br
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these numbers and consequently to an increase in the
number of older people with diabetes. Aged subjects with
diabetes have an increased rate of diabetes-related compli-
cations and are more likely to have comorbid conditions,
such as physical disability, cognitive dysfunction and de-
pression, all of which could impair health-related-quality-
of-life (HRQoL) [1].
Geriatric diabetes care guidelines recognize the import-
ance of improving HRQoL for older subjects with diabetes.
Almost all studies have compared HRQoL in older adults
with T2D with HRQoL in those without T2D. Studiesrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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on HRQoL and depressive symptoms in this population are
scarce. Three central goals in the treatment of diabetes mel-
litus are the avoidance of hyperglycaemia (prevention of the
development or progression of diabetes complications over
time), the avoidance of hypoglycaemia and the maintenance
or achievement of good HRQoL. Having multiple diabetic
complications is clearly associated with decreased HRQoL.
Data from large studies, such as the Diabetes Control and
Complications Trial (DCCT) and United Kingdom Pro-
spective Diabetes Study (UKPDS), suggest that intensive
treatment itself (using insulin or not) does not impair
HRQoL [2]. During past few years, interest in the associa-
tions between diabetes and HRQoL has grown consider-
ably. In the 1970s, just 13 studies mentioned the words
‘diabetes’ and ‘quality of life’ in their abstracts. A recent
research in pubmed has retrieved 8518 citations.
HRQoL is defined as a multidimensional concept in-
cluding not only the domains of physical health and
functioning, but also concern about the future. Having
diabetes for some subjects may have a different meaning
which is strongly influenced by a person’s value and per-
sonality. The self-report is the best way to measure
HRQol. Generic and diabetes-specific questionnaires are
accepted as preferred tools for its assessment. The term
HRQoL also includes physical, psychological and social
domains related to the health [3].
The role of insulin therapy over HRQoL of patients
with diabetes is controversial. Data from A1chieve study,
which evaluated people with T2D with unsatisfactory
glycemic control, has showed benefit of starting insulin
on HRQoL of the sample studied. In this study, people
with T2D starting insulin significantly improved overall
HRQoL across all component health dimensions. How-
ever, the average age of the population in the study was
54.9 (±14.4) years. So far, we could not extrapolate these
data to elderly population [4]. A systematic review and
meta-analysis of 11 trials compared the effects of treat-
ment with regular insulin versus short-acting insulin
analogues over HRQoL of patients with diabetes. It con-
cluded that objective interpretation on the results was
not possible due to the various instruments used [5].
Other study, which has not been included in that meta-
analysis, found that the combination insulin glargine
plus insulin lispro improved HRQoL in comparison with
NPH insulin and regular insulin [6]. Otherwise, in
Horvath’s meta-analysis no evidence for beneficial effect of
long-acting analogues on HRQoL could be observed [7].
The link between depressive symptoms and T2D remains
unknown. If depression was a causal factor for the develop-
ment of T2D, depressed patients would be at an increased
risk of developing pre-diabetes, which is not true. A sugges-
tion of a link between depression and diabetes comes from
reports of a positive association between continuousmeasures of depression (eg, severity scores) and serum glu-
cose levels (eg, fasting glucose, 2 h post-load glucose, or
HbA1c concentration). However, it had also been showed
that both hypoglycaemia as well hyperglycaemia were asso-
ciated with higher levels of depressive symptoms, contra-
dicting the idea of a direct link between depression and
dysglycaemia [8]. The role of insulin therapy on depressive
symptoms is also not well established. Although there is
some evidence depressive symptoms seem to be more
prevalent in subjects with T2D under insulin therapy, there
also exists data showing this therapy is not associated with
an increase in such risk [9, 10].
Finally, the role of insulin therapy over depressive symp-
toms and HRQoL in adults with T2D remains controver-
sial. Indeed, it has not been studying specifically in elderly
population so far. The aim of our study was to evaluate the
role of insulin therapy on depressive symptoms as well
HRQoL of elderly people with T2D. Our study is especially
of value because of its prospective design.
Subjects, materials and methods
Patient selection and procedures
The Brazilian National Institute of Health defines as an eld-
erly a person who is 60 years or older. Patients with 60
years or older and diabetes from the outpatient unit of
nutrology and diabetes from Hospital Universitário Clem-
entino Fraga Filho with indication of starting insulin ther-
apy between January 2012 and June 2013 were invited to be
included in the research. We adopted a convenience sam-
ple, one of the main types of non-probability sampling
methods. Patients who had been included gave written in-
formed consent to participate. Data was collected using
paper and pen in the waiting room. The Research and Eth-
ics Committee of Federal University of Rio de Janeiro,
Brazil, approved the study protocol, participant information
sheet, and consent inform. We have recruited thirty-six pa-
tients were recruited, 10 of which did not complete follow
up. We excluded one of them from the research due to se-
vere episode of hypoglycemia and subsequent interruption
of insulin therapy. We evaluated all the participants at
monthly intervals in the 6 months of the study and the as-
sistant physician adjusted the dosage schedule of insulin
therapy when necessary.
Short-Form 36 Health Survey (SF-36), Problem Areas
in Diabetes (PAID) and Beck Depression Inventory
(BDI) questionnaires, body mass index (BMI), waist
circumference and glycosylated hemoglobin (HbA1c)
have been recorded at baseline and 6 months after the
beginning of insulin therapy. Socio-demographics char-
acteristics (gender, marital status and educational level),
presence of complications related to T2D and comorbid-
ities were also registered. The ophthalmologist examined
all patients and evaluated the presence/degree of diabetic
retinopathy by fundoscopy in mydriasis. Neuropathy was
Table 1 Baseline numerical and categorical variable of the
sample (n = 26)
Numerical baseline Median Minimum Maximum
Age (years) 66 60 79
BMI (Kg/m2) 28.1 21 41.3
Waist circumference (cm) 100.5 76 129
Hb A1C (%) 8.7 7.6 13.2
Number of medications 7 3 14
Years of T2D 8.5 1 37
Categorical baseline N %
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Weinstein pressure asthesiometer. The 24-hour urinary
excretion of albumin (UAER) was measured. UAER was
considered abnormal when it was > 30 mg/24 h. Micro-
albuminuria was defined as 30–300 mg/24 h and
macroalbuminuria as > 300 mg/24 h. All patients with
micro or macroalbuminuria were defined as having
nephropathy. Hypoglycemia was defined as blood glucose
< 50 mg/dL in the presence or not of clinical symptoms.
HRQoL was measured using a generic (Brazilian
version of the SF-36 Health Survey: SF-36) and a disease-
specific questionnaire (Problem Areas in Diabetes: PAID).
SF-36 provides scores related to both the physical and
mental dimensions of HRQoL. This scale consists of 36
items, which constitutes 8 domains: physical function
(PF), role physical (RP), bodily pain (BP), general health
perceptions (GH), vitality (VT), social functioning (SF),
role emotional (RE), and mental health (MH). Scores
ranged from 0 to 100, with higher scores indicating bet-
ter quality of life in those dimensions [11]. The Brazilian
edition of PAID consists of a 20-item self-report meas-
ure of diabetes-related emotional distress with high
internal reliability, sensitivity to change, and clinical
utility. It includes 20 questions that assess diabetes-
related stressors. The score is rescaled from 0 to 100,
with a high score indicating lower disease-specific
HRQoL or greater emotional distress related to diabetes
[12–14]. Portuguese version of the Beck Depression
Inventory (BDI) reliably enables physicians of the pres-
ence and severity of depressive symptoms. It is based on
the Diagnostic and Statistical Manual, 4th edition (DSM
IV, 1994) criteria. The assessment has a minimum score
of 0 and a maximum score of 63, with a high score indi-
cating worse depressive symptoms. [15] Patients were
excluded from the study if they had a history of chronic
kidney disease stages III/IV, dementia, coronary or
peripheral artery disease, organ transplant, cancer or
use of anti-depressant medications.
Statistical analysis
Data was analyzed using SAS 6.11 (SPSS Inc, Chicago, IL,
USA). Numerical variables were expressed as mean,
standard deviation (SD), median, minimum and max-
imum. Categorical data was expressed in percentage
(%). The distribution of the sample was analyzed by
Kolmogorov-Smirnoff test. Comparison between the
two time periods (before/after insulin) has been per-
formed by Wilcoxon test for the numerical variables and
by McNemar’s test for categorical data. Non-parametric
tests were used because the sample did not present a
Gaussian distribution. To verify the existence of a sig-
nificant association between range of scores (SF-36,
PAID and BDI) and baseline categorical variables
the Mann-Whitney’s test was used, and to verify theassociation with baseline numerical variables the Spear-
man’ s rank correlation coefficient (rs) was used. A p-value
smaller than 0.05 on the two-tail was considered to indi-
cate statistical significance.
Results
Thirty-six T2D patients (67.9 % females, age 66.5 ± 5.1
years) were recruited, 26 of whom completed the
follow-up. Generic (Short-Form 36 Health Survey - SF-
36) and specific (Problem Areas in Diabetes - PAID)
HRQoL questionnaires, Beck Depression Inventory
(BDI), clinical, laboratorial and socio-demographic data
were recorded at baseline and after 6 months of insulin
therapy. Baseline characteristics of the sample are
shown in Table 1.
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report in a Brazilian sample, in which the mean was
10.0 (p = 0.07). So we could infer that our sample was
relatively representative of our population [15]. There
was a significant reduction in HbA1c levels (8.7 vs 7.9;
p = 0.019). There were no significant changes in BMI
(28.1vs 28.3; p = 0.62) and waist circumference (100.5 vs
99.5; p =0.77). There was a significant reduction in BDI
score when compared to baseline values (10.5 vs 7.0;
p = 0.008), indicating an improvement in depressive
symptoms. Despite the robust drop in BDI score, HRQoL
did not change significantly in any of domains when the
total sample was analyzed as a whole, as shown in Table 2.
However, when correlation between the range of
scores (BDI, SF-36 and PAID), baseline variables and
their respective ranges has been assessed, it was shown
that there was an negative correlation between BDI
range and physical functioning (rs = −0.393; p = 0.038),
physical role (rs = −0.394; p = 0.038) and pain ranges
(rs = −0.427; p = 0.023) as well between baseline BDI
score and BDI range (rs = −0.608; p = 0.001). Otherwise,
there was a positive correlation between the BDI range
and PAID range (rs = 0.397; p = 0.037).
We also observed a trend of positive correlation
between the range of BDI score and HbA1c levels
(rs = 0.337; p = 0.080, which means that the higher the
reduction in HbA1c levels, the higher the improvement
in depressive symptoms.
When gender and educational level have been taken
into account, It was observed that men had a greater im-
provement in physical functioning domain than womenTable 2 Anthropometric variables, BDI, SF-36 and PAID scores







BMI (Kg/m2) 28.1 28.3 0.62 0.13
Waist circumference (cm) 100.5 99.5 0.77 −0.36
Hb A1C (%) 8.7 7.9 0.019 −0.84
BDI 10.5 7.0 0.008 −3.61
Physical functioning 52.5 55.0 0.68 1.25
Role-physical 25.0 50.0 0.13 8.93
Bodily pain 51.5 61.0 0.31 5.79
General health 53,5 52.0 0,34 4.96
Vitality 52.5 57.5 0.47 2.14
Social functioning 75.0 87.5 0.43 4.91
Role- emotional 66.6 83.3 0.74 3.57
Mental health 68 70.0 0.45 1.71
Mental health 68 70.0 0.45 1.71
PAID 20.5 16.5 0.23 −4.11
BMI body mass index, HbA1C hemoglobin glycated, BDI Beck depression
inventory, PAID Problem areas in diabetes(12.8 + 6.0 vs −4.2 + 3.7; p = 0.018) as well those with
higher educational level did in mental health domain
when compared with those with lower levels (7.4 + 5.2
vs −3.2 + 2.6; p = 0.017).
As far as chronic complications related to T2D are
concerned, participants with or without retinopathy or
neuropathy did not present any statistical difference in the
BDI (−2.9 + 2.0 vs - 4.2 + 1.6; p = 0.55) and HRQoL results
(PAID: −0.5 + 5.8 vs −7.2 + 3.0; p = 0.41). However, partici-
pants with nephropathy had a lower range in physical
functioning than those without nephropathy (7.7 + 12.1 vs
10.0 + 6.8; p = 0.010). Data is shown in Table 3.
Discussion
This is to the best of our knowledge the first research
that evaluates prospectively the association of starting
insulin therapy with HRQoL and depressive symptoms
specifically in elderly with T2D. Given the unique char-
acteristics of this population (elevated prevalence of
cardiovascular disease, frailty, increased risk of falls,
more deleterious consequences from a hypoglycemic
episode), it is of value that studies evaluating this spe-
cific population are conducted. Indeed, this population
is more vulnerable to lose their independence and the
introduction of insulin therapy increases treatment com-
plexity, requiring some cognitive and visual skills [2].
We observed that starting insulin therapy in elderly
participants with T2D was associated with significant
improvement in depressive symptoms, as indicated by
an important reduction in BDI score. We also found that
the higher the improvement in depressive symptoms,
the higher the improvement in physical functioning and
role physical, as well as in pain domain. The influence of
depressive symptoms in HRQoL of people with T2D is
known and has been published elsewhere [16]. Recent
data indicated a higher prevalence of depression in a
Brazilian population with T2D and a consequent reduc-
tion in its HRQoL, most notably in physical functioning
and physical role. However, this study evaluated subjects
aged between 40–60 years. Therefore, we can not ex-
trapolate these data [17]. Another study examined the
relationship between severity of depressive symptoms
and diabetes-related emotional distress in patients with
T2D and evaluated whether this relationship is inde-
pendent of demographic and clinical characteristics,
such as sex, age, duration of diabetes, glycemic control,
and diabetic complications. This study used the same
questionnaires used in our research (SF-36, PAID and
BDI). The results indicated that diabetes-related emo-
tional distress (PAID) was significantly related to the
severity of depressive symptoms. On multivariate ana-
lysis by regression model, it was found that this relation
was independent of the demographic, including age,
clinical characteristics, and therapeutic regimens [18].
Table 3 Correlation between BDI, SF-36 and PAID range and baseline numerical variables and their respective ranges













Baseline Age rs 0.139 −0.084 0.041 −0.323 0.285 0.026 −0.284 −0.305 0.052
BMI rs −0.201 0.158 0.301 −0.058 0.161 0.149 −0.061 0.046 0.235
Waist circumference rs −0.167 0.204 0.203 −0.182 0.105 0.278 −0.028 −0.166 0.179
Hb A1C rs −0.121 −0.092 0.082 0.093 0.287 −0.018 −0.050 0.138 0.238
BDI rs −0.608 −0.039 0.268 0.250 0.107 −0.048 0.076 0.012 −0.118
p 0.001
Range (after/before) BMI rs 0.276 −0.098 −0.142 −0.103 0.090 0.014 −0.022 0.074 0.010
Waist circumference rs 0.196 0.008 −0.141 −0.363 0.003 0.162 −0.047 0.214 0.134
HbA1C rs 0.337 −0.121 −0.221 −0.149 −0.306 −0.051 0.050 −0.033 −0.132
BDI rs −0.393 −0.394 −0.427 −0.347 −0.309 −0.368 −0.162 −0.288
p 0.038 0.038 0.023 0.071 0.11 0.054 0.41 0.14
rs: Spearman’ s rank correlation coefficient; p: value. p values not shown did not achieved statistical significance
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PAID ranges, which signifies the higher the improve-
ment on depressive symptoms, the bigger the improve-
ment on HRQoL complaints registered in PAID score.
We also found an inverse correlation between baseline
BDI score and BDI range, which means the more se-
verely depressed the individual at baseline, the smaller
the improvement on depressive symptoms.
We did not find a clear change in HRQoL scores.
However, when gender and educational level have
been taken into account, we also observed that men
had a greater improvement in physical functioning
domain than women. This gender interaction with
HRQoL has also been showed previously by Eljedi
et al. His group have studied a sample of patients
with T2D and evaluated HRQoL in this population in
a cross-sectional design. Their results indicated that
HRQoL of patients with T2D was strongly reduced
and indeed identified that women were specially af-
fected [19]. In Zhang’s study, it has also been identi-
fied an interaction between HRQoL and gender, and
women were more severely affected [20]. Likewise,
women did worse than men in Wandel’s review and
in Akinci’s study [21, 22].
Educational level seems also to have a different mean-
ing on our population. Participants with higher educa-
tional levels had a greater improvement in mental
health when compared with those with lower educa-
tional levels, as previously shown [23]. Our patients
with nephropathy had a worse outcome in physical
functioning when compared to those without this co-
morbidity. Although these data have to be reassured,
there is some available evidence indicating that protein-
uria per se plays a role in HRQoL of patients with dia-
betic nephropathy [24].Finally, we observed a trend of direct correlation be-
tween the range of BDI score and HbA1c levels, which
means that the higher the reduction in HbA1c levels,
the higher the improvement in depressive symptoms.
However, this did not achieve statistical significance,
possibly because of relatively small sample.
Indeed our data showed reduction in HbA1c levels, al-
though of smaller magnitude than in non-elderly adult
population studies, presumably because of the lower
doses used in our sample (related to less strict glycemic
targets) and the relatively short follow-up [4–7]. We did
not observe an increase in body weight as described in
other studies possibly for the same reasons [25].
The major limitation of our study is its relatively small
sample size that could have influenced the statistical
power to show a significant change in HRQoL scores.
However, the number of individuals included is similar
to the studies published previously [16, 26]. We adopted
a convenience sample and have taken into account the
study of Kamoi and cols, in which a prospective com-
parison of different types of insulin scheme has been
performed, as a model. They have studied a smaller
number of subjects than our study and have showed that
HRQoL of patients treated by continuous subcutaneous
insulin therapy is superior to that treated by multiple
daily insulin injections (p < 0.05). The results in SF-36
and PAID scores were very similar, when whole sample
was analyzed, which makes improbable that if the sam-
ple was greater we would find significant differences.
However, it is important to note that the exclusion of
the case of serious hypoglycemia may have influenced
the results. The participants lost in the follow up maybe
could have been those in whom insulin therapy had a
different meaning. It could be also considered a bias.
Furthermore, the design of the study (lack of a control-
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that the increase in BDI score was related to insulin
therapy or to the improvement in glycemic control. A
possible improvement in depressive symptoms related to
the starting of insulin therapy in elderly diabetic subjects
could be relevant in clinical setting in which starting in-
sulin faces some barriers, especially in elderly subjects.
However, these data must be investigated in a random-
ized controlled study and further research is warranted.
Conclusions
In our study, the beginning of insulin therapy in elderly
participants with T2D was associated with a significant
improvement in depressive symptoms and did not seem
to affect adversely the HRQoL of this population, both
fundamental aspects when deciding for any therapy
directed to people with T2D.
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